Medtronic on Edwards' tail with US Evolut R approval
This article was originally published in Clinica
Executive Summary
The US FDA has approved Medtronic's second-generation transcatheter aortic valve replacement system, CoreValve Evolut R, just a week after the agency gave the green light to the company’s arch TAVR rival, Edwards Lifesciences.